Estrogen receptor α attenuates transforming growth factor-β signaling in breast cancer cells independent from agonistic and antagonistic ligands

Breast Cancer Research and Treatment

Volumn 120, Issue 2, 2010, Pages 357-367

  Stope, Matthias B ^a   Popp, Simone L ^a   Knabbe, Cornelius ^b   Buck, Miriam B ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

Crosstalk; Estrogen receptor; Transforming growth factor

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTOR CROSS-TALK; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 77950691767     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0393-2     Document Type: Article

References (45)

1. 1. Harris L, Fritsche H, Mennel R et al (2007) American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312. doi: 10.1200/JCO.2007.14.2364 (Pubitemid 350232263)
2. 2. Knight WA, Livingston RB, Gregory EJ et al (1977) Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37:4669-4671 (Pubitemid 8239679)
3. Matthews J, Gustafsson J-A (2003) Estrogen signaling: a subtle balance between ERα and ERβ. MoL Interv 3:281-292. doi: 10.1124/mi.3.5.281.
4. Nilsson S, Mäkelä S, Treuter E et al (2001) Mechansim of estrogen action. Physiol Rev 81:1535-1565
5. 5. Hawse JR, Subramaniam M, Ingle JN et al (2008) EstrogenTGFβ cross-talk in bone and other cell types: role of TIEG, Runx2, and other transcription factors. J Cell Biochem 106:383 392. doi:10.1002/jcb.21425 (Pubitemid 351171910)
6. 6. Knabbe C, Lippman ME, Wakefield LM et al (1987) Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417 428. doi: 10.1016/0092-8674(87) 90193-0 (Pubitemid 18095356)
7. Roberts AB, Wakefield LM (2003) The two faces of transforming growth factor ß in carcinogenesis. Proc Natl Acad Sci USA 100:8621-8623. doi: 10.1073/pnas.1633291100
8. 8. Kaminska B, Wesolowska A, Danilkiewicz M (2005) TGF beta signalling and its role in tumor pathogenesis. Acta Biochim Pol 52:329-337 (Pubitemid 41133768)
9. Westerhausen DR, Hopkins WE, Billadello JJ (1991) Multiple transforming growth factor-β-inducible elements regulate expression of the plaminogen activator inhibitor type-1 gene in Hep G2 cells, J Biol Chem 266:1092-1100
10. 10. Dickson RB, Kasid A, Huff KK et al (1987) Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17β-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci USA 84:837-841. doi: 10.1073/pnas.84.3.837 (Pubitemid 17033902)
11. 11. Buck MB, von der Fecht J, Knabbe C (2002) Antiestrogenic regulation of transforming growth factor beta receptor I and II in human breast cancer cells. Ann N Y Acad Sci 963:140-143 (Pubitemid 34721705)
12. 12. Brandt S, Kopp A, Grage B et al (2003) Effects of tamoxifen on transcriptional level of transforming growth factor beta (TGF-beta) isoforms 1 and 2 in tumor tissue during primary treatment of patients with, breast cancer. Anticancer Res 23:223-229 (Pubitemid 36358522)
13. 13. Buck MB, Pfizenmaier K, Knabbe C (2004) Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-β pathway in human breast cancer. Mol Endocrinol 18:1643-1657. doi: 10.1210/me.2003-0278 (Pubitemid 38859573)
14. Buck MB, Fritz P, Dippon J et al (2004) Prognostic significance of transforming growth factor β receptor II in estrogene receptornegative breast cancer patients. Clin Cancer Res 10:491-498. doi: 10.11.58/1078-0432.CCR- 0320-03
15. Rae JM, Creighton CJ, Meek JM et al (2007) MDA-MB-435 cells are derived from M14 melanoma cells - a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 104:13-19. doi : 10.1007/s10549-006-9392-8
16. 16. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS (1986) Phenol red in tissue cultur media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 83:2496-2500. doi:10.1073/pnas.83.8.2496 (Pubitemid 16026909)
17. Wrana JL, Attisano L, Carcamo J et al (1992) TGFβ signals through a heteromeric protein kinase complex. Cell 71:1003-1014. doi:10.1016/0092-8674(92) 90395-S
18. 18. Dai JL, Turnacioglu KK, Schutte M et al (1998) Dpc4 transcriptional activation and dysfunction in cancer cells. Cancer Res 58:4592-4597 (Pubitemid 28480621)
19. 19. Andersson S, Davis DL, Dahlbäck H et al (1989) Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. J Biol Chem. 264:8222-8229 (Pubitemid 19137311)
20. Lai C-F, Feng X, Nishimura R et al (2000) Transforming growth factor-β up-regulates the β5 integrin subunit expression via Sp1 and Smad signaling. J Biol Chem 275:36400-36406. doi: 10.1074/jbc.M002131200
21. Edwards DR, Murphy G, Reynolds JJ et al (1987) Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibtor. EMBO J 6:1899-1904
22. 22. Massague J, Wotton D (2000) Transcriptional control by the TGF-β/Smad signaling system. EMBO J 19:1745-1754. doi: 10.1093/emboj/19.8. 1745 (Pubitemid 30204386)
23. Hall M-C, Young DA, Waters JG et al (2003) The comparative role of activator protein 1 and Smad factors in the regulation of Timp-1 and MMP-1 gene expression by transforming growth factor-β1. J Biol Chem 278:10304-10313. doi:10.1074/jbc. M212334200
24. Revillion F, Pawlowski V, Hornez L et al (2000) Glyceraldehyde3-phosphate dehydrogenase gene expression in human breast cancer. Eur J Cancer 36:1038-1042. doi:10.1016/S0959-8049 (00)00051-54
25. Van der Burg B, Van Selm-Miltenburg AJ, Laat SWD et al (1989) Direct effects of estrogen on c-fos and c-myc protoon-cogene expression and cellular proliferation in human breast cancer cells. Mol Cell Endocrinol 64:223-228. doi: 10.1016/0303-7207(89)90.149-4
26. 26. Müller V, Jensen EV, Knabbe C (1998) Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines. Cancer Res 58:263-267 (Pubitemid 28047065)
27. Wakeling AE, Dukes M, Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867-3873
28. 28. Brünner N, Frandsen TL, Holst-Hansen C et al (1993) MCF7/ LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antoestrogen ICI 182;780. Cancer Res 53:3229-3232 (Pubitemid 23223286)
29. Burdette JE, Woodruff TK (2007) Activin and estrogen crosstalk regulates transcription in human breast cancer cells. Endocr Relat Cancer 14:679-689. doi:.10.1677/ERC-07-0054
30. 30. Qi X, Borowicz S, Pramanik R et al (2004) Estrogen receptor inhibits c-jun-dependent stress-induced cell death by binding and modifying c-jun activity in human breast cancer cells. J Biol Chem 279:6769-6777. doi:1.0.1.074/jbc.M311492200 (Pubitemid 38248818)
31. Teyssier C, Belguise K, Galtier F et al (2001) Characterization of the physical interaction between estrogen receptor α and JUN proteins. J Biol Chem 276:36361-36369. doi:10.1074/jbc.M101 806200
32. 32. Matsuda T, Yamamoto T, Muraguchi A et al (2001) Cross-talk between transforming growth factor-β and estrogen receptor signaling through Smad3. J Biol Chem 276:42908-42914. doi: 10.1074/jbc.M105316200 (Pubitemid 37370969)
33. 33. Wu L, Wu Y, Gainings B et al (2003) Smad4 as a transcription corepressor for estrogen receptor α. J Biol Chem 278:15192-15200. doi: 10.1074/jbc.M212332200 (Pubitemid 36799854)
34. 34. Green KA, Carroll JS (2007) Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Natl Rev 7:713-722 (Pubitemid 47327416)
35. 35. Foekens JA, Schmitt M, van Putten. WL et al (1994) Plasminogen activator inhibitor-1 and prognosis on primary breast cancer. J Clin Oncol 12:1648-1658 (Pubitemid 24245001)
36. 36. Tian F, Byfield SD, Parks WT et al (2003) Reduction in Smad2/3 signaling enhances tumorigenesis but supresses metastasis of breast cancer cell lines. Cancer Res 63:8284-8292 (Pubitemid 37549480)
37. 37. Jänicke F, Schmitt M, Pache L et al (1993) Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer, Breast Cancer Res Treat 24:195-208. doi: 10.1007/BF01833260 (Pubitemid 23062819)
38. 38. Roberts AB, Tian F, Byfield SD et al (2006) Smad3 is key to TGF-β-mediated epithelial-to-mesenchymal transition, fibrosis, tumor supression and metastasis. Cytokine Growth Factor Rev 17:19-27. doi:1.0.1.016/j.cytogfr.2005.09.008 (Pubitemid 43117513)
39. Bover L, Barrio M, Bravo AI et al (1998) The human breast cancer cell line IIB-BR-G has amplified c-myc and c-fos onco-genes in vitro and is spontaneously metastatic in vivo. Cell Mol Biol (Noisy-le-grand) 44:493-504
40. 40. Rich MA, Furmanski P, Brooks SC (1978) Prognostic value of estrogen receptor determinations in patients with breast cancer. Cancer Res 38:4296-4298 (Pubitemid 9054221)
41. Foekens JA, Look MP, Peters HA et al (1995) Urokinase-type plasminogen activator and its inhibitor PAI-1 : predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87:751-756. doi: 10.1093/jnci/87.10.751
42. Han B, Nakamura M, Mori I et al (2005) Urokinase-type plasminogen activator system and breast cancer. Oncol Rep 14:105-112 review
43. Harrell JC, Dye WW, Allred DC et al (2006) Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res 66:9308-9315. doi:10.1158/0008-5472.CAN-061769
44. 44. Odekon LE, Blasi F, Rifkin DB (1994) Requirement for receptorbound urokinase in plasmin-dependent cellular conversion of latent TGF-β to TGF-β. J Cell Physiol 158:398-407. doi: 10.1002/jcp.1041580303 (Pubitemid 24094420)
45. Delany AM, Canalis E (2001) The metastasis-associated metalloproteinase stromelysin-3 is induced by transforming growth factor-β in osteoblasts and fibroblasts. Endocrinology 142:1561-1566. doi: 10.1210/en.142.4.1561